Evidence map›Paper›PMID 38993217›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2021

Surface Labeling with Adhesion Protein FimH Improves Binding of Immunotherapeutic Agent

Maroeska J Burggraaf, Lisette Waanders, Mariska Verlaan, Janneke Maaskant, Diane Houben, Joen Luirink, Wilbert Bitter, Coen Kuijl, Carla F M Molthoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maroeska J BurggraafDepartment of Medical Microbiology and Infection Control, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Lisette WaandersDepartment of Medical Microbiology and Infection Control, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Mariska VerlaanDepartment of Radiology & Nuclear Medicine, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Janneke MaaskantDepartment of Medical Microbiology and Infection Control, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Diane HoubenSection Molecular Microbiology, AIMMS, Vrije Universiteit, Amsterdam, The Netherlands.
Joen LuirinkAbera bioscience AB, Solna, Sweden.
Wilbert BitterDepartment of Medical Microbiology and Infection Control, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Coen KuijlDepartment of Medical Microbiology and Infection Control, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.
Carla F M MolthoffDepartment of Radiology & Nuclear Medicine, Amsterdam University Medical Center (AUMC), Location VU Medical Center (VUMC), Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer is the ninth most common cancer in men. 70% of these tumors are classified as non-muscle invasive bladder cancer and those patients receive 6 intravesical instillations with

objectiveTo increase the binding of Ty21a to the bladder wall by surface labeling of the bacteria with adhesion protein FimH and to study its effect in a bladder cancer mouse model.

methodsBinding of Ty21a with surface-labeled FimH to the bladder wall was analyzed

resultsFimH-labeled Ty21a showed significant (

conclusionsFimH labeling of Ty21a significantly improved binding to bladder tumor cells

Indexed as

bladder cancerE. coliFimH proteinimmunotherapySalmonella entericaTy21a typhoid vaccine

Identifiers

PMID38993217
PMCPMC11181684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.